Condition (MeSH)
Hyperphosphatemia
ClinicalTrials.gov lists 163 trials for Hyperphosphatemia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
163 of the 163 trials are tagged with Hyperphosphatemia itself; the rest are tagged with a narrower condition beneath it.
When did Hyperphosphatemia trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 8 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 8 |
| 2019 | 10 |
| 2018 | 6 |
| 2017 | 8 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 22 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 128 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperphosphatemia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 27 |
| Phase 2/3 | 2 |
| Phase 3 | 53 |
| Phase 4 | 18 |
| Not applicable | 28 |
| Observational | 24 |
How many Hyperphosphatemia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 117 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperphosphatemia trials? (13)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 10 |
| Tanabe Pharma Corporation | 10 |
| Astellas Pharma Inc | 8 |
| Kyowa Kirin Co., Ltd. | 7 |
| Ardelyx | 6 |
Showing 5 of 13 sponsors.
Which drugs are being tested for Hyperphosphatemia? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sevelamer Carbonate | 18 |
| Sevelamer | 14 |
| Tenapanor | 13 |
| PA21 | 11 |
| ASP1585 | 8 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule | 17 |
| Ferric Citrate | 11 |
| Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet | 3 |
| Fermagate | 3 |
| ER Niacin | 2 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperphosphatemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 69 | 17 |
| Sepsis | 58 | 13 |
| Hypertension | 36 | 11 |
| Renal transplant | 36 | 7 |
| Cardiac failure congestive | 35 | 11 |
Showing 5 of 10 adverse events.
Which publications cover Hyperphosphatemia? (114)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Pathologic Actions of Phosphate in CKD. | Kidney360 | 2025 | Yes |
| Lanthanum carbonate lowers serum phosphorus without altering body phosphorus burden in maintenance peritoneal dialysis patients: a randomized crossover trial. | The American journal of clinical nutrition | 2025 | Yes |
| Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. | Kidney360 | 2024 | Yes |
| Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study. | Nephron | 2024 | Yes |
| Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial. | Clinical and experimental nephrology | 2024 | Yes |
Showing 5 of 114 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.